Advanced Biomed Inc (ADVB) FinancialsADVBAdvanced Biomed Inc

Evaluating the bottom line, Advanced Biomed Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 71.33%, provide a clear picture of how effectively ADVB converts its operational activities into shareholder value.

In the context of the broader market, ADVB competes directly with industry leaders such as CALC and CODX. With a market capitalization of $6.58M, it holds a significant position in the sector. When comparing efficiency, ADVB's gross margin of N/A stands against CALC's N/A and CODX's -48.76%. Such benchmarking helps identify whether Advanced Biomed Inc is trading at a premium or discount relative to its financial performance.

The financial performance shows volatility with net income fluctuating, including a significant loss of $1,384,874 in Q3 2025, but a positive net income of $6,857,921 in Q2 2026. However, the overall trend remains concerning with negative earnings per share (EPS) in most quarters, including -0.38 in Q3 2026.